In vitro, pasireotide and octreotide have already been compared for their efficacy against primary human somatotropinoma (GH-secreting-PTs) [27], corticotropinoma (ACTH-secreting) [28] and also NFPT cells [17]. The gene discussed is POMC; the disease is ACTH-producing pituitary gland adenoma.